Radiomic phenotypes in nonmuscle‐invasive bladder cancer: A precision biomarker guiding therapy
Cancer · 15.08.2026 · 132 (16)
DOI: 10.1002/cncr.70563 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer, online erschienen am 06.08.2026. Verfasst von Colton H Walker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Magnetic resonance imaging radiomics shows promise in guiding the selection of patients most likely to benefit from the use of immune checkpoint inhibitor therapy in patients with very‐high‐risk, nonmuscle‐invasive bladder cancer. This work arrives at a moment of rapid expansion in bladder‐sparing therapeutics, even as biomarker‐guided patient selection remains conspicuously absent across the field.
Autor:innen und Institutionen
- Department of Urology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Cancer Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Colton H Walker, Navid Jabalameli, Soroush Rais-Bahrami
Zitieren
APA
Walker, C. H., Jabalameli, N., & Rais-Bahrami, S. (2026). Radiomic phenotypes in nonmuscle‐invasive bladder cancer: A precision biomarker guiding therapy. Cancer, 132(16). https://doi.org/10.1002/cncr.70563
Vancouver
Walker CH, Jabalameli N, Rais-Bahrami S. Radiomic phenotypes in nonmuscle‐invasive bladder cancer: A precision biomarker guiding therapy. Cancer. 2026;132(16). doi:10.1002/cncr.70563
BibTeX
@article{Walker2026,
author = {Walker, Colton H and Jabalameli, Navid and Rais-Bahrami, Soroush},
title = {Radiomic phenotypes in nonmuscle‐invasive bladder cancer: A precision biomarker guiding therapy},
journal = {Cancer},
year = {2026},
volume = {132},
number = {16},
doi = {10.1002/cncr.70563}
}
EUVIMED